About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North Growth Market. Short name: SEZI.

Press releases

Senzime’s Interim report January – September 2019

Read more

100 TetraGraph systems to Japan after regulatory approval

Read more
See all »

News

Launch of TetraGraph Philips Interface

Read more

New research data proves the value of accurate monitoring of patients after use of muscle relaxants

Read more

Presented research from Mayo Clinic proves TetraGraph ease of use

Read more
See all »